Pediatric Clinical Trials
Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma
RATIONALE: Vaccines made from a person's cancer cells may make the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood and may stimulate the immune system in different ways and stop cancer cells from growing.
PURPOSE: This phase II trial is studying how well giving vaccine therapy together with GM-CSF works in treating patients with progressive B-cell non-Hodgkin's lymphoma.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: autologous immunoglobulin idiotype-KLH conjugate vaccine
- biological: sargramostim
Eligibility
DISEASE CHARACTERISTICS:
- Histologically confirmed follicular B-cell non-Hodgkin's lymphoma (NHL)
- Grade 1, 2, or 3
- Progressive disease AND did not receive autologous immunoglobulin idiotype-KLH
conjugate vaccine (FavId™) while enrolled on protocol FAV-ID-06
- Meets 1 of the following criteria:
- Received salvage therapy after completion of protocol FAV-ID-06
- At least 4 weeks, but no more than 4 months, since prior salvage therapy
- Did not receive salvage therapy after completion of protocol FAV-ID-06
- At least 4 weeks, but no more than 4 months, since completion of prior
treatment on protocol FAV-ID-06
- No history of CNS lymphoma OR meningeal lymphomatosis
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Cardiovascular
- No history of congestive heart failure
Pulmonary
- No history of compromised pulmonary function
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- No active bacterial, viral, or fungal infection
- No psychiatric disorder
- No other serious nonmalignant disease that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- No prior allogeneic transplantation*
- No prior rituximab regimen* other than that administered on protocol FAV-ID-06
(rituximab 375 mg/m^2 IV weekly for 4 weeks)
Chemotherapy
- No prior purine analogues* (e.g., fludarabine or cladribine)
Endocrine therapy
- No prior or concurrent steroids (e.g., steroid doses in excess of daily replacement)
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- Recovered from prior salvage therapy
- No prior or concurrent immunosuppressive therapy
- No prior investigational agents*
- No other concurrent antilymphoma therapy NOTE: *As salvage therapy administered
between completion of protocol FAV-ID-06 and enrollment onto this study
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mayita Romero
6507256452
Not Recruiting